Buy UNCY by Sep 21, 2026.

Unicycive Therapeutics ($UNCY - $7.87 - Mark cap: 210M) is a late-stage biotech focused on kidney disease treatments. Its lead product, **Oxylanthanum Carbonate (OLC)**, is a next-generation phosphate binder for chronic kidney disease (CKD) patients on dialysis. OLC is designed to reduce pill burden while maintaining phosphate control, potentially improving patient compliance. ([Unicycive Therapeutics, Inc.](https://ir.unicycive.com/news/detail/111/unicycive-therapeutics-provides-update-from-fda-type-a?utm_source=chatgpt.com)) **Why June 29 matters** * FDA PDUFA date: June 29 * Potential transition from development-stage to commercial-stage company * Large addressable dialysis market * Elevated …